New drug combo shows promise against tough liver cancer
NCT ID NCT03463876
First seen Feb 22, 2026 · Last updated May 21, 2026 · Updated 14 times
Summary
This study tested a combination of two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), in 190 adults with advanced liver cancer that had stopped responding to or could not tolerate prior treatment. The goal was to see if the combo could shrink tumors and how safe it was. Participants received the drugs and were monitored for tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Beijing, Beijing Municipality, 100071, China
Conditions
Explore the condition pages connected to this study.